Libido draft — topics missed and what the evidence actually shows

Status: draft compiled 2026-04-28

The user's draft on libido pharmacology is missing or undertreating an entire series of topics that any serious evidence map has to carry. The claim that bremelanotide / PT-141 was "the FDA-approved direct libido drug" is the most conspicuous omission, because flibanserin came first by four years and its approval is one of the most consequential and contested events in the history of regulated sexual-medicine pharmacology. Beyond that single error, the draft underrepresents the dopamine system that does most of the heavy lifting in human sexual motivation, treats oxytocin and vasopressin as if their human evidence were as clean as the prairie-vole story, omits the kisspeptin programme that may actually become the next class of libido drugs, and gives short shrift to the placebo effect that swamps every clinical trial in this domain. It also leaves out aging-and-libido epidemiology, the diagnostic shift from HSDD to FSIAD, Basson's responsive-desire framework, and the Coolidge effect, which between them explain more variance in real-world libido than any pharmacology can. Below I work through each missed topic in flowing prose with inline citations and per-paragraph confidence tags, then close with a ranked list of what mattered most.

Flibanserin (Addyi) — the actually first FDA-approved HSDD drug

Flibanserin is the original FDA-approved drug for hypoactive sexual desire disorder in premenopausal women, granted approval in August 2015 under NDA 022526 and marketed by Sprout Pharmaceuticals as Addyi. The user's draft inverted the chronology by treating bremelanotide as the prototype: bremelanotide (Vyleesi) was not approved until June 2019, four years later. Flibanserin's pharmacology is also very different from bremelanotide's. It is a daily, chronic, oral 100 mg bedtime tablet whose effect emerges over weeks, not an on-demand subcutaneous injection. Mechanistically it is best described as a "multifunctional serotonin agonist and antagonist" or a norepinephrine-dopamine disinhibitor: a full agonist at 5-HT1A in the prefrontal cortex and dorsal raphe, an antagonist at 5-HT2A, and a very weak partial agonist at dopamine D4. The downstream consequence in animal microdialysis is increased prefrontal dopamine and norepinephrine and decreased 5-HT, which Stahl framed as a corrective re-balancing in brain regions where reduced sexual interest correlates with abnormal neuroimaging signatures. None of this is the cleanly "central libido" story sometimes told in lay press, but it is the actual mechanistic claim the regulator credited. Sources: FDA approval letter NDA 022526, Stahl 2015 mechanism review, CNS Spectrums, Joffe 2016 NEJM perspective. Confidence: C1 for the dates and pharmacological mechanism, C2 for the network-level interpretation.

The approval was contentious in a way that is hard to overstate. The FDA rejected flibanserin twice — first in 2010, when an advisory committee voted unanimously against approval citing inadequate risk-benefit, and again in 2013 — before Sprout reorganised the dossier and engaged in what eventually became the "Even The Score" advocacy campaign. Even The Score claimed that the FDA had approved 26 drugs for male sexual dysfunction and zero for women, which was simply not true; it was bankrolled by Sprout via Blue Engine Media, and several of the women who testified at the 2015 advisory meeting in support of approval had been brought there by the company. Critics including the Hastings Center and the National Women's Health Network argued that this was a case of pharmaceutical marketing weaponising feminist framing to lower the regulator's risk-benefit threshold; supporters argued that the FDA had set an unreasonably high bar for any female sexual-medicine drug. The advisory committee in June 2015 voted 18-6 to recommend approval with risk-management measures, and the FDA approved the drug two months later with a Risk Evaluation and Mitigation Strategy (REMS), a boxed warning about hypotension and syncope, and a near-absolute alcohol contraindication. The approval pathway is now a textbook case in how patient advocacy, gender politics, and pharmaceutical PR can interact with regulatory science. Sources: Joffe 2016 NEJM perspective, BuzzFeed News investigation, Hastings Center "The Score is Even", Nature 524:387 commentary on FDA vulnerability. Confidence: C1-C2.

The effect size that all that political energy was fighting over is, by the actual meta-analysis, modest. Jaspers et al. published the definitive systematic review and meta-analysis in JAMA Internal Medicine in 2016, pooling eight trials of flibanserin against placebo in women with HSDD or FSIAD. The mean difference in satisfying sexual events per month was about 0.49 — roughly half of one additional event monthly — with a similarly small bump on the FSFI desire and FSDS-R distress scales. Adverse effects, by contrast, were not subtle: dizziness was about four times more common than on placebo, and somnolence, fatigue, and nausea were each roughly doubled. Jaspers and colleagues rated the quality of evidence as "very low" because of design limitations, indirectness, and a publication-bias signal in which published trials were systematically more favourable than unpublished ones. The result is one of those cases where a technically positive p-value for a clinically tiny effect collides with a clinically meaningful safety burden, and reasonable physicians can defensibly land on either side of the prescribing decision. Sources: Jaspers et al. 2016, PMID 26927498, JAMA Intern Med, Erasmus University Jaspers preprint record. Confidence: C1.

The alcohol story matters because it is one of the few cases where a contentious post-marketing study materially changed a label. The original 2015 label included a boxed warning and a contraindication against alcohol use entirely, on the basis of a Phase 1 study that had a near-all-male population — a methodology that critics pilloried as making the very mistake the Even The Score campaign was supposed to be fixing. After post-marketing studies in women, in April 2019 the FDA ordered Sprout to soften the warning so that women could drink up to one or two drinks if they then waited two hours before the bedtime dose; if three or more drinks had been consumed, they should skip that night's dose. In October 2019 the FDA further removed the alcohol contraindication and the REMS certification requirement, although the boxed warning about hypotension and syncope remained. Commercially the drug had already foundered: low uptake, requirement for daily dosing, the alcohol restriction during the most uptake-sensitive years, and a small effect size that was hard to brand convincingly all combined to make Addyi a textbook example of an FDA-approved drug that lost its market. Sources: Healio April 2019 label-change report, BioSpace 2019 alcohol-ban removal, FDA 2025 ADDYI label, NDA 022526s013. Confidence: C1.

Bremelanotide (Vyleesi) and the right framing of the melanocortin route

For completeness rather than novelty: bremelanotide is the second FDA-approved HSDD drug, approved June 2019 for premenopausal women with acquired, generalised HSDD. It is a melanocortin receptor agonist, given as an on-demand subcutaneous autoinjection roughly 45 minutes before anticipated activity, and it acts centrally on MC4R-expressing pathways implicated in sexual motivation rather than peripherally on blood flow. In the integrated Phase 3 dataset the responder rate was 58.2% on bremelanotide versus 35.6% on placebo, but the placebo response rate alone exceeds the active-minus-placebo delta of flibanserin, which is exactly the methodological warning the user's draft does not foreground. Nausea occurs in roughly 40% of users and is the dominant tolerability signal; transient mild systolic blood pressure increases of about 6 mmHg are why uncontrolled hypertension and cardiovascular disease are listed as contraindications. The right framing is that bremelanotide is the second, not first, regulator-credentialed libido drug, and that on-demand pharmacology is conceptually different from the chronic-modulator pharmacology of flibanserin. Sources: Bremelanotide Wikipedia summary with FDA dates, Rao & Andrade 2020 Indian J Psychol Med review, Mayer & Lynch 2020 review. Confidence: C2.

The dopamine system the draft underweights

Apomorphine is the cleanest example of a centrally dopaminergic drug used for sexual function. It is a non-selective D1/D2 receptor agonist, and Abbott marketed a sublingual formulation as Uprima in the EU starting May 2001 for erectile dysfunction. The Marketing Authorisation was not renewed for commercial reasons, and the drug formally lapsed on 28 May 2006. The clinical literature consistently describes onset within about 15-25 minutes after sublingual dosing, with rates of dose-limiting nausea, dizziness, headache, and occasional syncope — the same dopaminergic side effects that limit apomorphine's other indications, including Parkinson's disease. Apomorphine was the closest the field came to a centrally dopaminergic on-demand ED drug, and its commercial failure tells us something important: people will accept a noticeable rate of nausea and faintness for sexual benefit, but the threshold is not infinite, and PDE5 inhibitors offered a far cleaner side-effect profile. Sources: EMA Uprima EPAR record, Heaton 2001 PMID 11477485, DrugBank apomorphine entry. Confidence: C1 for the regulatory record, C2 for the side-effect framing.

The Parkinson's literature provides the natural-experiment evidence on what dopamine D3-preferring agonism does to human sexuality. Pramipexole and ropinirole induce impulse-control disorders, of which hypersexuality is one of the four canonical presentations alongside pathological gambling, compulsive shopping, and binge eating. Aggregate prevalence in pramipexole-treated populations is approximately 32% for any ICD and 25% for ropinirole; hypersexuality specifically affects roughly 2-8% of pramipexole-treated patients. The mechanistic story is that pramipexole is relatively selective for D3 over D2 receptors compared with other agonists, and D3 receptor density is high in mesolimbic regions associated with reward and motivation, so pharmacologically up-regulating D3-mediated signalling appears to drive a clinically recognisable hypersexual phenotype. Importantly there is no clean dose-response for pramipexole-associated ICDs, which suggests an idiosyncratic susceptibility rather than a simple "more drug, more behaviour" relationship. This is the strongest naturalistic evidence in humans that artificially boosting D3-skewed dopaminergic transmission can dramatically increase sexual motivation, and it is one of the reasons the dopamine pathway remains a credible target for future libido drug development despite the failure of apomorphine sublingual. Sources: Voon et al. ICD review, PMC2924724, Seeman 2015 D3 hypothesis, PMID 25645960, Frontiers in Psychiatry 2021 ICD review. Confidence: C2.

Bupropion is the dopaminergic-noradrenergic drug that the draft ought to have credited. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) marketed as an atypical antidepressant and as a smoking cessation aid (Wellbutrin, Zyban). Crucially, in head-to-head and pooled comparisons it does not produce the SSRI-class sexual dysfunction signature, and a substantial randomised-trial literature suggests it can rescue SSRI-induced sexual dysfunction when added on or substituted. Clayton et al.'s 2004 trial of sustained-release bupropion 150 mg twice daily in SSRI-induced sexual dysfunction showed significant improvements in desire, arousal, and orgasm. A 2022-2024 wave of systematic reviews including women-specific analyses found bupropion SR 150 mg twice daily the most effective pharmacological treatment for antidepressant-induced sexual dysfunction in women, although with low certainty. There are also small RCTs of bupropion for HSDD as a primary indication, with directionally positive but not regulatory-grade signals. The relevant clinical message is that for many patients the right answer to "my SSRI killed my libido" is not a melanocortin or 5-HT1A drug but a direct switch or augmentation strategy with a dopaminergic antidepressant. Sources: Clayton et al. 2004 J Clin Psychiatry, PMID 11894796, Bupropion-women systematic review, PMC9886814, Pharmacological treatment of AISD meta-analysis, PMC11904590. Confidence: C2.

The conceptual frame the draft is missing is Berridge and Robinson's "wanting versus liking" dissociation. From the early 1990s onwards, Berridge's lab at Michigan and Robinson's collaborators showed in rodents that mesolimbic dopamine is necessary for incentive salience or "wanting" but not for the hedonic impact or "liking" of consumption. Amphetamine microinjected into the nucleus accumbens increased instrumental responding for sucrose ("wanting") without increasing facial-affect "liking" reactions to sucrose tasted directly. Conversely, lesions to mu-opioid hedonic hotspots in ventral pallidum and nucleus accumbens reduce "liking" without abolishing "wanting." The 30-year incentive-sensitization theory of addiction generalises this to compulsive behaviour: in dependence, "wanting" can grow pathologically while "liking" plateaus or shrinks. Applied to libido, this framework predicts that drugs that crank dopamine — pramipexole, methamphetamine, cocaine — produce hypersexual urges that are not necessarily accompanied by greater pleasure, and it predicts that drugs targeting the hedonic-opioid system will produce different and probably smaller effects on spontaneous urge. It is the theoretical lens the draft most needs, because it explains why "boost dopamine" is not a clean win and why melanocortin and serotonergic interventions occupy fundamentally different conceptual slots. Sources: Berridge 2007 Psychopharmacology review, PMID 17072591, Berridge & Robinson 1998 Brain Res Rev, PMID 9858756, Robinson & Berridge 2024 30-years review, Annu Rev Psychol. Confidence: C1.

Stimulant-induced hypersexuality is the population-scale shadow of all this. Methamphetamine acutely increases sexual desire, lengthens activity, lowers risk-perception, and is well documented to associate with compulsive sexual behaviour and elevated HIV/STI risk especially in MSM populations, with chemsex literature triangulating heavily on this point. Cocaine has similar acute effects with shorter duration and less consistent hypersexuality, and chronic use of either drug ultimately produces tolerance and frequent sexual dysfunction. The relevant biology is that both agents elevate synaptic dopamine — cocaine by blocking the dopamine transporter, amphetamines by reversing it — but adaptation, including reduced striatal D2/D3 receptor binding, develops with sustained use. The lesson for the libido draft is that endogenous dopamine elevation is real, behaviourally potent, but homeostatically defended; chronic exogenous "more dopamine" delivers acute hypersexuality that erodes into long-term hypoactivity. Sources: JAMA Psychiatry meta-analysis on stimulants and dopamine, 2017, Frohmader et al. methamphetamine compulsive sex Neuropsychopharmacology, CDC consultation on methamphetamine and sexual risk PMC1525267. Confidence: C2.

Oxytocin and vasopressin — the popularity-versus-evidence gap

Oxytocin is the runaway pop-science star of sexual neurochemistry, and the actual evidence is much less clean than the press releases. Carmichael et al. 1987 in J Clin Endocrinol Metab is the foundational human study: blood-sampled men and women self-stimulated to orgasm, and plasma oxytocin rose during arousal and peaked at orgasm. The peripheral spike is reproducible. The conceptual leap to pair-bonding in humans is much weaker, because most randomised intranasal-oxytocin trials in humans have produced small or null effects on classical sexual function endpoints. MacDonald et al. 2013 found that a single 24 IU intranasal oxytocin dose in heterosexual couples did not change sexual drive, arousal, erection, or lubrication, although it did increase reported orgasm intensity, post-coital contentment, and study-participation experience, with stronger effects in men. Muin et al. 2015 in Fertil Steril ran a 22-week crossover trial of long-term intranasal oxytocin against placebo in women with sexual dysfunction and found that both arms improved over time, with no oxytocin-specific advantage — a textbook example of placebo-and-time confounded with active treatment. Behnia et al. 2014 also found no oxytocin effect on subjective sexual function in healthy women. There is a longstanding methodological problem with intranasal delivery in that bioavailability to deep brain regions is uncertain, and central oxytocin levels are not well predicted by peripheral or nasal-spray administration; recent reviews argue that systemic oxytocin concentrations may be largely orthogonal to behaviour. Sources: Carmichael et al. 1987, PMID 3782434, MacDonald et al. 2014 Horm Behav, PMID 24503174, Muin et al. 2015 Fertil Steril, PMID 26151620, Leng & Sabatier 2021 systematic review, PMC8360917. Confidence: C2.

Vasopressin is the partner pair-bonding hormone in the prairie-vole literature. Winslow et al. 1993 in Nature showed that central V1a-like AVP receptor blockade in monogamous prairie voles (Microtus ochrogaster) prevents partner-preference formation after mating, with promiscuous montane voles (Microtus montanus) showing different AVP-receptor distribution. Insel and colleagues then extended this to oxytocin and to dense receptor mapping in nucleus accumbens and ventral pallidum. The vole data are pretty, but their relevance to humans is repeatedly overstated in popular accounts. Human trials of intranasal AVP and oxytocin on attachment-style endpoints exist but are small, mixed, and sometimes contradictory, and the AVPR1A polymorphism literature in humans is much less compelling than the original vole story implied. The honest summary is that voles told us neuropeptides could biologically gate pair-bond formation, but they do not give us a human pharmacological lever. Sources: Winslow et al. 1993 Nature, PMID 8413608, Insel review chapter, Donaldson & Young 2008 voles review, ScienceDirect. Confidence: C2.

Kisspeptin — the most credible candidate for the next libido drug class

Kisspeptin is the peptide that the draft most needed to flag as a forward-looking lever. The KISS1 gene encodes kisspeptin, which signals through KISS1R (formerly GPR54) to drive GnRH neurons and reproductive function; loss-of-function mutations cause hypogonadotropic hypogonadism. Comninos and colleagues at Imperial College London have built an unusually clean translational programme around its central effects on sexual processing. Comninos et al. 2017 in J Clin Invest gave intravenous kisspeptin or vehicle to 29 healthy heterosexual men in a double-blind crossover with fMRI and found that kisspeptin enhanced limbic and paralimbic activity to sexual cues, and that this enhancement correlated with reduced sexual aversion. A 2018 paper in PNAS using resting-state fMRI showed kisspeptin altered limbic connectivity. The 2022 JAMA Network Open trial of intravenous kisspeptin in men with HSDD (Comninos et al., PMID 36735255) showed enhanced sexual brain processing and increased penile tumescence, and the parallel 2022 JAMA Network Open trial in women with HSDD (PMID 36287566) showed modulation of sexual and facial-attraction processing in the predicted direction. None of this is yet a drug; kisspeptin is administered intravenously, orally bioavailable analogues are in early development, and the responder-level effects in HSDD are not yet well-characterised. But it is genuinely the most exciting near-future candidate class for libido pharmacology, because the mechanism (central GnRH-axis modulator with limbic effects) is more upstream than anything the FDA has yet credentialed. Sources: Comninos et al. 2017 J Clin Invest, PMID 28112678, Comninos et al. 2018 PNAS resting-state, PMID 30333302, Comninos et al. 2022 men HSDD JAMA Netw Open, PMID 36735255, Mills et al. 2022 women HSDD JAMA Netw Open, PMID 36287566. Confidence: C2.

Yohimbine — old, modestly useful, mostly for psychogenic ED

Yohimbine is an alpha-2 adrenoceptor antagonist derived from the bark of Pausinystalia johimbe. The Ernst & Pittler 1998 systematic review and meta-analysis in J Urol pooled seven trials of yohimbine for erectile dysfunction and reported an odds ratio of about 3.85 in favour of yohimbine over placebo, with the effect concentrated in psychogenic and mixed-aetiology ED. The classic Reid et al. 1987 Lancet trial in psychogenic impotence showed roughly 62% response on 18 mg/day yohimbine versus 16% on placebo. Side effects include anxiety, palpitations, transient hypertension, headache, and in susceptible individuals panic attacks; the supplement-grade "yohimbine HCl" sold as a fat-burner is not the same standardised pharmaceutical formulation that produced those trial signals, and cases of contamination, mis-dosing, and frank toxicity have been reported. Yohimbine is also one of the few sexual-pharmacology agents with a credible mechanistic basis for being more useful in psychogenic than organic ED, because alpha-2 antagonism at central and peripheral noradrenergic sites is more relevant when sympathetic over-tone is the inhibiting mechanism than when the limit is vascular. Sources: Ernst & Pittler 1998 J Urol meta-analysis, PMID 9649257, Reid et al. 1987 Lancet trial PMID, Cui et al. 2022 systematic review, PMC9612744. Confidence: C2.

Botanical and supplement evidence — separating real from hype

Maca (Lepidium meyenii) is the most defensible non-prescription option in this space. Shin et al. 2010 in BMC Complement Altern Med (PMID 20691074) systematically reviewed four RCTs and found "limited evidence" of benefit for sexual function in healthy men and women, with the trials' total sample size and quality too low to generalise confidently. Gonzales' Lima group has produced multiple small RCTs showing modest libido improvements in healthy men, women using SSRIs, and postmenopausal women, with the consistent finding that maca's effect does not depend on serum testosterone. Dording et al. 2008 and 2015 ran double-blind dose-finding trials of maca for SSRI-induced sexual dysfunction in women and reported significant improvements in sexual function and libido with 3.0 g/day. The mechanism is unknown, with hypotheses ranging from glucosinolate/macamide effects on monoamine systems to placebo-amplified ritual effect. The honest summary is "modest, plausibly real, mechanism unclear, side-effect profile benign." Sources: Shin et al. 2010 BMC review, PMID 20691074, Dording et al. 2015 dose-finding trial, PMC6494062, Gonzales 2002 Andrologia desire study. Confidence: C2-C3.

Tribulus terrestris is the supplement-aisle counter-example. The cumulative human evidence is that Tribulus does not meaningfully raise testosterone in eugonadal men, despite decades of marketing claims. Pokrywka et al. 2014 in Phytomedicine and a 2025 Nutrients systematic review in Lopes et al. agreed that Tribulus has a low-quality evidence base for erectile function and no robust evidence for raising testosterone or LH. There are isolated small RCTs reporting benefit for overall sexual function via mechanisms hypothesised to involve nitric oxide or steroidal saponins, but the methodological quality is poor and effects are inconsistent. For female sexual dysfunction the evidence is weaker still. The right summary for any honest libido map is that Tribulus is a popular supplement with weak evidence and persistent overclaiming. Sources: Lopes et al. 2025 Nutrients systematic review, PMC11990417, Pokrywka et al. 2014 systematic review, PMID 24559105, OPSS Tribulus monograph. Confidence: C2.

Korean red ginseng (Panax ginseng) sits between maca and Tribulus on the evidence hierarchy. Jang et al. 2008 PMID 18754850 systematically reviewed seven RCTs of red ginseng for ED and found a pooled risk ratio of about 2.40 favouring ginseng over placebo, with subgroup benefit in psychogenic ED. The 2021 Cochrane review by Lee et al. PMID 33871063 / 34169686 was much more conservative, concluding that ginseng appears to have only a "trivial effect" on erectile dysfunction relative to placebo, with low-certainty evidence from heterogeneous trials. The mechanistic story involves ginsenosides Rb1, Rg1, and Rg3 interacting with nitric-oxide signalling and possibly central neurotransmission, but the gap between mechanistic plausibility and clinical effect size is wide. Korean red ginseng is reasonable to test as an adjunct for mild ED, especially when patients want a supplement-tier intervention before progressing to PDE5 inhibitors, but it is not a libido drug in the strict sense and its effect-size estimates have decreased as trial quality has increased. Sources: Jang et al. 2008, PMID 18754850, Lee et al. 2021 Cochrane, PMID 33871063, Lee et al. 2021 World J Mens Health summary. Confidence: C2.

L-arginine and L-citrulline are nitric-oxide precursors. L-citrulline is converted in the kidneys to L-arginine, which is the substrate for nitric oxide synthase. Cormio et al. 2011 showed L-citrulline 1.5 g/day improved erection hardness in mild ED. Rhim et al. 2019 in Sex Med Rev pooled ten RCTs of L-arginine 1.5-5 g/day in 540 ED patients and found significant improvement on erectile function scores. A 2021 Italian multi-centre trial of high-dose L-arginine 6 g/day for three months in vasculogenic ED also showed significant benefit. None of this is a libido drug; the mechanism is peripheral vascular, the effect is on erectile mechanics rather than desire, and the supplement is best framed as a milder lower-cost analogue of PDE5 inhibition with weaker evidence and weaker effect. Sources: Cormio et al. 2011 L-citrulline trial, PMID 21195829, Rhim et al. 2019 Sex Med Rev meta-analysis, Italian multi-centre L-arginine RCT, PMC8995264. Confidence: C2.

Saffron (Crocus sativus) is the surprise on this list because the evidence is more credible than its botanical-supplement positioning suggests. Modabbernia et al. 2012 PMID 23280545 ran a double-blind RCT of saffron 30 mg/day in women with fluoxetine-induced sexual dysfunction and found improvements in arousal, lubrication, and pain compared with placebo. Subsequent trials extended this to men with antidepressant-induced sexual dysfunction. Saffron has independent evidence for mild-to-moderate depression with effect sizes comparable to fluoxetine and imipramine in some meta-analyses, which complicates interpretation: is the sexual benefit a saffron-specific aphrodisiac effect or downstream rescue from depression? Either way, the side-effect profile is clean, and saffron is the supplement most likely to deserve a tentative recommendation in SSRI-induced sexual dysfunction when bupropion substitution is undesirable. Sources: Modabbernia et al. 2012 fluoxetine-women trial, PMID 23280545, Toth et al. 2019 saffron sexual dysfunction meta-analysis, Lopresti & Drummond 2014 saffron review, PMID 25384672. Confidence: C2.

Fenugreek is a small-effect testosterone booster with separable libido effects. Mansoori et al. 2020 PMID 32048383 meta-analysed seven RCTs in male athletes and found small standardised mean differences for total testosterone (SMD 0.32) and free testosterone (SMD 0.24); a 2023 systematic review with meta-analysis broadly agreed. Industry-sponsored Testofen trials have reported significant improvements in libido subdomains in middle-aged and older men, but the evidence base is heavily concentrated in trials funded by extract manufacturers. The honest summary is small, real, and partly explained by something other than testosterone. Sources: Mansoori et al. 2020 meta-analysis, PMID 32048383, Smith et al. 2023 Planta Medica systematic review, PMID 37253363, Steels et al. 2011 Testofen libido trial, PMID 21312304. Confidence: C2.

Icariin (Epimedium / horny goat weed) is interesting because it actually has a real mechanism — weak phosphodiesterase type 5 inhibition — but is roughly 80-fold less potent than sildenafil in vitro, and oral bioavailability in humans is poor. Shindel et al. 2010 PMID 20141584 demonstrated PDE5 inhibitory activity and erectogenic effects in cavernous-nerve-injured rats. Brown et al. 2019 PK study in healthy adults found near-undetectable plasma levels at oral doses up to 1,680 mg/day. Combine these and you get a plausible mechanism, real animal data, and a tiny clinical signal. The "horny goat weed" market overstates the benefit; the research direction (better-bioavailable icariin analogues) is more interesting than the supplement itself. Sources: Shindel et al. 2010 J Sex Med, PMID 20141584, Brown et al. 2019 icariin PK trial, Examine.com horny goat weed monograph. Confidence: C2-C3.

Oysters and chocolate deserve a debunking paragraph rather than respect. Oysters contain large amounts of zinc, and severe zinc deficiency can impair testosterone production, but normal-zinc-status men do not gain testosterone or libido by eating zinc-rich foods, and human trials of zinc supplementation for libido in eugonadal men show no meaningful effect. Chocolate contains phenylethylamine and small amounts of theobromine and caffeine, and the most-cited Salonia 2006 study found no significant effect of chocolate consumption on female sexual function above lifestyle confounders. Both foods are aphrodisiacs in the cultural-symbolic sense — context, ritual, and expectation drive measurable sexual outcomes — and that is exactly the placebo-effect literature speaking. Sources: Salonia et al. 2006 study summarised, Cleveland Clinic aphrodisiacs review, McGill OSS oysters debunk. Confidence: C2.

Trazodone, naltrexone, MDMA — three conceptually different cases

Trazodone is a serotonergic antidepressant with potent alpha-1 adrenergic blockade. It does not enhance libido, but it is worth mentioning because it produces priapism in a small but clinically real fraction of users — incidence around 1 in 1,000 to 1 in 10,000 prescriptions in some series, and roughly 0.45% in one population study. The mechanism is alpha-1 blockade impairing sympathetically driven detumescence rather than direct erectogenic action. Trazodone has actually been informally tried as an erectogenic agent and as an SSRI sexual-dysfunction rescue, with mixed and largely disappointing data. Its main relevance to a libido map is as a cautionary note: alpha-1 blockade is enough to derange erection physiology dangerously even when the drug has nothing to do with central sexual drive. Sources: Saenz de Tejada et al. 1991 priapism mechanism, PMID 1984101, Ramírez-Backhaus AJP RJ trazodone priapism case review. Confidence: C2.

Naltrexone is a non-selective opioid antagonist (mu, kappa, delta) approved for opioid-use disorder and alcohol-use disorder. It has been used off-label for compulsive sexual behaviour disorder (CSB), informally called "sex addiction." Bostwick & Bucci 2008 Mayo Clin Proc reported naltrexone monotherapy resolving compulsive internet-pornography use; subsequent case series, the 2020 Kraus feasibility study in 20 men (PMID 32532705), and the 2022 Lew-Starowicz World Psychiatry RCT all supported naltrexone's role as an adjunct or monotherapy for CSB symptoms. The hypothesised mechanism is blockade of mu-opioid contributions to dopaminergic activity in mesolimbic reward circuits, which Berridge's hedonic-hotspot work in fact predicts. There are anecdotal reports and small case series of naltrexone in post-SSRI sexual dysfunction (PSSD), but the evidence is thin, the mechanism speculative, and the potential for paradoxical effects (decreased pleasurable sensation) real. Naltrexone is also relevant because it pharmacologically tests the opioid-hedonic-system hypothesis of sexual reward in a way that the dopaminergic and serotonergic literatures cannot. Sources: Bostwick & Bucci 2008 Mayo Clin Proc, Kraus et al. 2020 feasibility study, PMID 32532705, Lew-Starowicz et al. 2022 World Psychiatry. Confidence: C2.

MDMA is the empathogen-class case. Acutely it produces a 5-HT-driven prosocial state, with downstream peripheral oxytocin elevation, increased emotional empathy and social approach, reduced threat-detection, and frequently disinhibited sexual behaviour. Bedi et al. 2014 Soc Cogn Affect Neurosci showed enhanced emotional empathy and prosocial behaviour after a controlled dose. Kamilar-Britt & Bedi 2015 reviewed the controlled-laboratory evidence and confirmed robust prosocial effects in humans with consistent acute increases in plasma oxytocin. The chronic-effects literature is more troubling: heavy MDMA use is associated with serotonergic dysregulation, depressive sexual side effects, and erectile difficulty, and animal data show down-regulation of multiple monoaminergic markers. The libido takeaway is that empathogens acutely enhance partnered sexual context but produce no clean chronic libido benefit, and recreational chronic exposure may damage the same circuits the acute dose enhances. Sources: Hysek et al. 2014 SCAN MDMA empathy, PMC4221206, Bedi et al. 2010 empathogen study, PMC2997873, Kamilar-Britt & Bedi 2015 prosocial review, PMC4678620. Confidence: C2.

The placebo response, and why every libido drug has to be read against it

The single most important methodological point the draft skipped is that placebo response in sexual-dysfunction trials is enormous. In HSDD and FSAD trials, 35-45% of women on placebo meet responder criteria, which is approximately the active-arm responder rate of flibanserin and within striking distance of bremelanotide. The mechanisms are not mysterious: enrolling in a trial requires self-identification of distress, attention from clinicians, behavioural changes (regular tracking, partner conversations, mandatory sexual encounters), and the simple expectancy effect of being treated. Bradford & Meston have published methodological work on correlates of placebo response in female sexual dysfunction; the FSD trial literature has actively grappled with this for years. The implication is severe: any drug whose active-minus-placebo delta is one extra satisfying sexual event per month is operating in the noise floor of expectancy and behaviour change, and the case for prescribing it has to be built on individual responders rather than on aggregate effect sizes. Sources: Bradford 2017 listening to placebo, Bradford & Meston correlates of placebo response, Clayton et al. 2021 HSDD treatment overview, PMC8412154. Confidence: C2.

Aging, hypogonadism, and the natural history of male libido

The Massachusetts Male Aging Study (MMAS) is the foundational epidemiology. Feldman et al. 1994 in J Urol surveyed roughly 1,290 men aged 40-70 in Boston-area communities from 1987-1989 and reported that some degree of erectile dysfunction was present in approximately 52% of men in this age band, with prevalence rising sharply across the decade brackets. Johannes et al. 2000 J Urol PMID 10647654 followed the longitudinal cohort and estimated a crude annual incidence of about 26 cases per 1,000 man-years overall, with rates rising from about 12 per 1,000 in the 40-49 group to 46 per 1,000 in the 60-69 group. Cigarette smoking, diabetes, hypertension, and cardiovascular disease independently predict ED, and the inflection of the prevalence-by-age curve is what makes ED epidemiologically inseparable from cardiovascular epidemiology. The libido-versus-ED distinction matters here: MMAS measured ED, not desire, and although both decline with age and hypogonadism, they decline along different trajectories with different responsiveness to PDE5 inhibitors versus testosterone. Sources: Feldman et al. 1994 J Urol MMAS, PMID 8254833, Johannes et al. 2000 J Urol incidence, PMID 10647654. Confidence: C1.

The Testosterone Trials (TTrials) by Snyder and colleagues, published in NEJM in 2016, are the cleanest randomised evidence on what raising testosterone in older hypogonadal men does to libido. 790 men aged 65 or older with serum testosterone below 275 ng/dL and clinical symptoms received testosterone gel or placebo for one year; the Sexual Function Trial subset showed significant improvements in sexual activity, sexual desire, and erectile function, with effect sizes that were "moderate" rather than dramatic. Cunningham et al. 2016 J Clin Endocrinol Metab extended the analysis and showed that improvements in desire and activity correlated with the magnitude of testosterone and estradiol increase. The cardiovascular safety question, which had clouded the field after the 2010 testosterone-fall trial, was answered for moderate-risk older men by the TRAVERSE trial (Lincoff et al. 2023 NEJM), which found no excess cardiovascular events on testosterone gel relative to placebo in 5,246 men with cardiovascular risk. Together these trials give clinicians a defensible evidence base for treating clinically symptomatic hypogonadism in older men, while clearly delineating the limits — testosterone is a moderate libido lever in genuinely hypogonadal men, not a youth-restoration drug. Sources: Snyder et al. 2016 NEJM TTrials, PMID 26886521, Cunningham et al. 2016 sexual function detail, PMID 27355400, Lincoff et al. 2023 TRAVERSE NEJM. Confidence: C1.

Diagnostic frame — HSDD, FSIAD, Basson, and what is actually being treated

The DSM-5 in 2013 collapsed the DSM-IV-TR diagnoses of female hypoactive sexual desire disorder and female sexual arousal disorder into a single diagnosis of female sexual interest/arousal disorder (FSIAD), which the FDA-approved drugs flibanserin and bremelanotide were both originally tested for under the older HSDD label. The rationale was that desire and arousal in women are highly comorbid and conceptually entangled, especially in long-term partnered contexts, and that the artificial split obscured rather than clarified the clinical picture. The International Society for the Study of Women's Sexual Health and the International Consultation in Sexual Medicine objected vocally and continue to maintain a separate nosology that retains HSDD and FSAD as distinct disorders, on the argument that the new construct is too heterogeneous to be useful for trials and treatment-matching. From a libido-pharmacology standpoint this matters because it determines what is being measured: a drug effective for women whose problem is genuinely low spontaneous desire may look identical in trial data to a drug effective for women whose problem is responsive arousal failure, and the diagnostic merger increases that confusion. Sources: Brotto FSIAD critical review, ScienceDirect, SMSNA defining FSIAD article, DSM-5 / ICSM controversy, PMC. Confidence: C2.

Rosemary Basson's responsive-desire model is the underlying conceptual move that the DSM-5 was reflecting. Basson published her non-linear model in 2000-2002 in the J Sex Marital Ther and CMAJ. The core claim is that for many women — especially in long-term partnered contexts — desire is not a spontaneous drive that precedes engagement but a responsive state that emerges after the decision to engage and the experience of arousal. The "two-axes" framing the user gestured at in the draft is closer to Basson's distinction between responsive and spontaneous desire, with the further insight that emotional intimacy, relational context, and the rewards of past sexual engagement are not noise around the core biological signal but constitutive of desire itself. The clinical implication is that treating low desire by trying to pharmacologically generate spontaneous urge is conceptually incoherent for many women whose ordinary baseline never included spontaneous urge. This is also why partnered-context studies show such large placebo responses; the trial intervention is itself a relational intervention. Sources: Basson 2000 J Sex Marital Ther, PMID 10693116, Basson 2001 CMAJ Human sex-response cycles, PMID 11224952, Basson 2002 Womens sexual desire disordered or misunderstood, PMID 11898699. Confidence: C1.

The Coolidge effect and relationship-duration variance

The Coolidge effect is the phenomenon, first robustly demonstrated in rodents and then across many mammalian species, in which sexual interest and behavioural arousal are renewed when a sated male is exposed to a novel female partner. The mechanism involves dopamine in mesolimbic reward circuits — sexual habituation reduces nucleus accumbens dopamine release to the same partner over repeated exposures, and novel-partner exposure restores it. Translation to humans is methodologically harder because partner novelty in humans is confounded with relationship investment, attachment, and contextual variables, but partial parallels exist: Klusmann 2002 in Arch Sex Behav and subsequent work on relationship-duration declines in female sexual desire have shown that sexual interest declines with relationship duration in both sexes but more steeply in many women, controlling for age. The libido-pharmacology punchline is that for many people the dominant variable in their sexual-interest trajectory is relationship duration and relational context, not neurochemistry; expecting a daily 5-HT1A agonist to fix a Coolidge-effect-driven plateau is asking the drug to do something it cannot do. Sources: Wilson et al. 1963 original Coolidge data, summarised at Wiki, Murphy et al. hormones and Coolidge effect, Psychology Today summary of relational-novelty literature. Confidence: C3.

Most important things the draft missed — top 5 ranked

Flibanserin (Addyi) and the chronology error. The draft asserted that bremelanotide / PT-141 was the FDA-approved direct libido drug. Flibanserin was approved four years earlier in August 2015, has a fundamentally different pharmacology (chronic daily 5-HT1A/5-HT2A modulator with downstream dopaminergic effects rather than on-demand melanocortin agonist), and is the centre of one of the most consequential approval-controversies in sexual-medicine regulation. Missing this is not a minor omission; it inverts the actual history of the field. The Jaspers 2016 JAMA Internal Medicine meta-analysis is also load-bearing because it shows the active-minus-placebo effect is roughly half a satisfying sexual event per month, which any honest map has to communicate.

The placebo response problem. Across HSDD trials placebo responder rates run 35-45%, which is comparable to the active-arm rate for flibanserin and not far below bremelanotide. Without flagging this, every effect-size citation in the draft over-claims. Trial enrolment in this domain is itself a behavioural and relational intervention, and the entire interpretive frame for "did this drug work" has to be built around that fact.

The dopamine-and-wanting framework, including bupropion and the Parkinson's ICD literature. The draft underweighted dopamine. Bupropion is the underused libido-friendly antidepressant the draft did not flag as the obvious first-line answer to "my SSRI killed my libido." The pramipexole / ropinirole hypersexuality literature is the clean human natural experiment showing that artificially elevating D3-skewed dopaminergic transmission produces a real and recognisable hypersexual phenotype. Berridge & Robinson's wanting-versus-liking dissociation is the conceptual lens that explains why "more dopamine" is not a clean win.

Kisspeptin as the credible next-generation candidate. The Comninos / Imperial College programme of intravenous kisspeptin trials in HSDD men and women, with fMRI correlates of enhanced limbic processing of sexual cues and reduced sexual aversion, is the most exciting forward-looking pharmacology in the field. Skipping this misses where the science is actually moving.

Basson's responsive-desire model and the DSM-5 HSDD-to-FSIAD merger, plus the Coolidge effect. This is the conceptual cluster that explains why pharmacological interventions look so modest. If the dominant driver of partnered libido is relational context and responsive rather than spontaneous desire, and if relationship duration produces robust declines in spontaneous interest via a dopaminergic novelty-habituation mechanism, then drugs that try to manufacture spontaneous urge are going to produce small effects in randomised trials almost by construction. The diagnostic frame and the relational variance have to be in the libido map, or the pharmacology will look more important than it actually is.